NUMBER OF THE DAY
U.S. company Expedition Therapeutics has secured the global rights to Fosun Pharma’s experimental lung drug XH-S004 for this amount.
💊 Blockbuster potential: $17 million upfront, up to $103 million in development milestones, and $525 million tied to commercial success; Shanghai-based Fosun Pharma Industrial retains China-only rights.
🫁 Unmet medical need: The DPP-1 inhibitor targets chronic lung diseases such as COPD and bronchiectasis. There is currently no approved therapy worldwide with this mechanism.
Watch: This deal shows how Chinese pharma innovation is gaining momentum—global partnerships are becoming key to worldwide commercialization of breakthrough drugs.
The China Survival Guide for Western Businesses
Entity setup, WeChat strategy, hiring your first local team. 12+ years on the ground in Shanghai.
